Clinical Trials Logo
  1. Home
  2. Dengue Virus
  3. NCT02305732

A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components — TRUE  

Dengue Virus Clinical Trial

Official title:
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components

Clinical Trial Summary

The rationale for a Treatment Use Investigational Device Exemption (IDE) of INTERCEPT PCs is to address current gaps in platelet transfusion safety in selected geographic regions. The objective is to provide access to INTERCEPT PCs for patients who might be at risk of transfusion-transmitted infection (TTI) due to Chikungunya virus (CHIKV) and Dengue virus (DENV) in regions in which a substantial proportion of the population has been infected or is at risk of infection by these pathogens (Petersen 2014); and the risk of asymptomatic infection among qualified blood donors is recognized (Stramer 2012, Adda 2014).

The study is designed as a prospective, open label, multi-center, observational study to evaluate the safety and efficacy of INTERCEPT platelet components.

Clinical Trial Description

Upon written informed consent, patients will be transfused with study PCs according to local practices. Each patient will be supported with platelets as clinically indicated in a manner that is consistent with the local standard of care. The study will be conducted in two phases. During the pilot phase, patients will sign informed consent to have study data collected following transfusion with conventional PCs. The objective of the pilot phase is to evaluate study logistics and data collection methods. During the INTERCEPT Treatment Use phase, patients will sign informed consent to receive INTERCEPT PCs, provide blood samples, and collect study data (demographics, transfusion data, and safety data). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02305732
Study type Observational
Source Cerus Corporation
Contact
Status Completed
Phase
Start date March 2015
Completion date May 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT05507450 - Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) Phase 2
Completed NCT00788151 - Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Phase 2
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Active, not recruiting NCT03141138 - Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine Phase 1
Completed NCT00875524 - Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Phase 2
Completed NCT02794181 - Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
Completed NCT01073306 - Safety and Immune Response to an Investigational Dengue Type 2 Vaccine Phase 1
Completed NCT00842530 - Efficacy and Safety of Dengue Vaccine in Healthy Children Phase 2
Completed NCT00740155 - Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Phase 2
Completed NCT00730288 - Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Phase 2
Completed NCT00880893 - Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Phase 2
Completed NCT01084291 - Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine Phase 1
Completed NCT00617344 - Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Phase 2